{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T17:26:53Z","timestamp":1795282013121,"version":"4.10.3"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13023-019-1080-y","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T10:03:19Z","timestamp":1559124199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance"],"prefix":"10.1186","volume":"14","author":[{"name":"MPS Consensus Programme Steering Committee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Umut","family":"Akyol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MPS Consensus Programme Co-Chairs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tord D.","family":"Alden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Amartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Belani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Borgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Braunlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikatsu","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cengiz","family":"Karsli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane Ruschel","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McFadyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"McGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Muenzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torayuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-3686","authenticated-orcid":false,"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hendriksz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"issue":"Suppl 5","key":"1080_CR1","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2011","unstructured":"Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v4\u201312.","journal-title":"Rheumatology (Oxford)"},{"key":"1080_CR2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/jpc.13122","volume":"52","author":"RA James","year":"2016","unstructured":"James RA, Singh-Grewal D, Lee SJ, McGill J, Adib N, Australian Paediatric Rheumatology G. Lysosomal storage disorders: a review of the musculoskeletal features. J Paediatr Child Health. 2016;52:262\u201371.","journal-title":"J Paediatr Child Health"},{"key":"1080_CR3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00381-014-2578-1","volume":"31","author":"A Leone","year":"2015","unstructured":"Leone A, Rigante D, Amato DZ, Casale R, Pedone L, Magarelli N, et al. Spinal involvement in mucopolysaccharidoses: a review. Childs Nerv Syst. 2015;31:203\u201312.","journal-title":"Childs Nerv Syst"},{"key":"1080_CR4","doi-asserted-by":"crossref","first-page":"471325","DOI":"10.1155\/2012\/471325","volume":"2012","author":"MF Coutinho","year":"2012","unstructured":"Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage disorders: a review. Biochem Res Int. 2012;2012:471325.","journal-title":"Biochem Res Int"},{"key":"1080_CR5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11926-013-0389-0","volume":"16","author":"R Cimaz","year":"2014","unstructured":"Cimaz R, La Torre F. Mucopolysaccharidoses. Curr Rheumatol Rep. 2014;16:389.","journal-title":"Curr Rheumatol Rep"},{"key":"1080_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10545-013-9613-3","volume":"37","author":"LD Archer","year":"2014","unstructured":"Archer LD, Langford-Smith KJ, Bigger BW, Fildes JE. Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity. J Inherit Metab Dis. 2014;37:1\u201312.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","volume":"28","author":"F Baehner","year":"2005","unstructured":"Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005;28:1011\u20137.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1651-2227.2008.00965.x","volume":"97","author":"G Malm","year":"2008","unstructured":"Malm G, Lund AM, Mansson JE, Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr. 2008;97:1577\u201381.","journal-title":"Acta Paediatr"},{"key":"1080_CR9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-5-5","volume":"5","author":"V Valayannopoulos","year":"2010","unstructured":"Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010;5:5.","journal-title":"Orphanet J Rare Dis"},{"key":"1080_CR10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cbic.200700400","volume":"9","author":"A Silipo","year":"2008","unstructured":"Silipo A, Zhang Z, Canada FJ, Molinaro A, Linhardt RJ, Jimenez-Barbero J. Conformational analysis of a dermatan sulfate-derived tetrasaccharide by NMR, molecular modeling, and residual dipolar couplings. Chembiochem. 2008;9:240\u201352.","journal-title":"Chembiochem."},{"key":"1080_CR11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/labinvest.3780345","volume":"81","author":"CM Simonaro","year":"2001","unstructured":"Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Investig. 2001;81:1319\u201328.","journal-title":"Lab Investig"},{"key":"1080_CR12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1203\/01.PDR.0000156510.96253.5A","volume":"57","author":"CM Simonaro","year":"2005","unstructured":"Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res. 2005;57:701\u20137.","journal-title":"Pediatr Res"},{"key":"1080_CR13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.a.30579","volume":"134A","author":"SJ Swiedler","year":"2005","unstructured":"Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A. 2005;134A:144\u201350.","journal-title":"Am J Med Genet A"},{"key":"1080_CR14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1542\/peds.2006-2184","volume":"120","author":"R Giugliani","year":"2007","unstructured":"Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007;120:405\u201318.","journal-title":"Pediatrics."},{"key":"1080_CR15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10545-013-9587-1","volume":"36","author":"TC Wood","year":"2013","unstructured":"Wood TC, Harvey K, Beck M, Burin MG, Chien YH, Church HJ, et al. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis. 2013;36:293\u2013307.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ymgme.2011.08.024","volume":"104","author":"A Jurecka","year":"2011","unstructured":"Jurecka A, Golda A, Opoka-Winiarska V, Piotrowska E, Tylki-Szymanska A. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) with a predominantly cardiac phenotype. Mol Genet Metab. 2011;104:695\u20139.","journal-title":"Mol Genet Metab"},{"key":"1080_CR17","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"1080_CR18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","volume":"32","author":"F Hasson","year":"2000","unstructured":"Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32:1008\u201315.","journal-title":"J Adv Nurs"},{"key":"1080_CR19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67:401\u20139.","journal-title":"J Clin Epidemiol"},{"key":"1080_CR20","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","volume":"182","author":"MC Brouwers","year":"2010","unstructured":"Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182:E839\u201342.","journal-title":"CMAJ."},{"issue":"1","key":"1080_CR21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpainsymman.2018.03.023","volume":"56","author":"Juan M. Politei","year":"2018","unstructured":"Politei JM, Gordillo-Gonzalez G, Guelbert N, Souza CFM, Lourenco CM, Solano ML, et al. Recommendations for evaluation and management of pain in patients with mucopolysaccharidosis in Latin America. J Pain Symptom Manage. 2018;56(1):146\u201352.","journal-title":"Journal of Pain and Symptom Management"},{"key":"1080_CR22","first-page":"7257230","volume":"2017","author":"S Congedi","year":"2017","unstructured":"Congedi S, Di Pede C, Scarpa M, Rampazzo A, Benini F. The complexity of pain Management in Children Affected by Mucopolysaccharidoses. Case Rep Pediatr. 2017;2017:7257230.","journal-title":"Case Rep Pediatr"},{"key":"1080_CR23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ymgme.2017.05.008","volume":"121","author":"E Oussoren","year":"2017","unstructured":"Oussoren E, Bessems J, Pollet V, van der Meijden JC, van der Giessen LJ, Plug I, et al. A long term follow-up study of the development of hip disease in Mucopolysaccharidosis type VI. Mol Genet Metab. 2017;121:241\u201351.","journal-title":"Mol Genet Metab"},{"key":"1080_CR24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/PRM-2010-0108","volume":"3","author":"P Garcia","year":"2010","unstructured":"Garcia P, Sousa SB, Ling TP, Conceicao M, Seabra J, White KK, et al. Skeletal complications in mucopolysaccharidosis VI patients: case reports. J Pediatr Rehabil Med. 2010;3:63\u20139.","journal-title":"J Pediatr Rehabil Med"},{"key":"1080_CR25","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"P Harmatz","year":"2005","unstructured":"Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681\u20139.","journal-title":"Pediatrics."},{"key":"1080_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"Laboratories ATSCoPSfCPF","year":"2002","unstructured":"Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1080_CR27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2016.12.010","volume":"120","author":"F Kubaski","year":"2017","unstructured":"Kubaski F, Suzuki Y, Orii K, Giugliani R, Church HJ, Mason RW, et al. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses. Mol Genet Metab. 2017;120:247\u201354.","journal-title":"Mol Genet Metab"},{"key":"1080_CR28","doi-asserted-by":"crossref","first-page":"e0138622","DOI":"10.1371\/journal.pone.0138622","volume":"10","author":"EJ Langereis","year":"2015","unstructured":"Langereis EJ, Wagemans T, Kulik W, Lefeber DJ, van Lenthe H, Oussoren E, et al. A multiplex assay for the diagnosis of mucopolysaccharidoses and mucolipidoses. PLoS One. 2015;10:e0138622.","journal-title":"PLoS One"},{"key":"1080_CR29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2014.09.009","volume":"114","author":"H Zhang","year":"2015","unstructured":"Zhang H, Wood T, Young SP, Millington DS. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses. Mol Genet Metab. 2015;114:123\u20138.","journal-title":"Mol Genet Metab"},{"key":"1080_CR30","first-page":"Unit 17 2","volume":"Chapter 17","author":"H Zhang","year":"2013","unstructured":"Zhang H, Young SP, Millington DS. Quantification of glycosaminoglycans in urine by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry. Curr Protoc Hum Genet. 2013;Chapter 17:Unit 17 2.","journal-title":"Curr Protoc Hum Genet"},{"key":"1080_CR31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13023-014-0135-3","volume":"9","author":"CK Chuang","year":"2014","unstructured":"Chuang CK, Lin HY, Wang TJ, Tsai CC, Liu HL, Lin SP. A modified liquid chromatography\/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet J Rare Dis. 2014;9:135.","journal-title":"Orphanet J Rare Dis."},{"issue":"3","key":"1080_CR32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41436-018-0136-z","volume":"21","author":"Jennifer T. Saville","year":"2018","unstructured":"Saville JT, McDermott BK, Fletcher JM, Fuller M. Disease and subtype specific signatures enable precise diagnosis of the mucopolysaccharidoses. Genet Med. 2019;21(3):753\u201357.","journal-title":"Genetics in Medicine"},{"key":"1080_CR33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ymgme.2014.02.009","volume":"111","author":"SM Lin","year":"2014","unstructured":"Lin SM, Lin HY, Chuang CK, Lin SP, Chen MR. Cardiovascular abnormalities in Taiwanese patients with mucopolysaccharidosis. Mol Genet Metab. 2014;111:493\u20138.","journal-title":"Mol Genet Metab"},{"key":"1080_CR34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2143\/AC.60.1.2005049","volume":"60","author":"MR Chen","year":"2005","unstructured":"Chen MR, Lin SP, Hwang HK, Yu CH. Cardiovascular changes in mucopolysaccharidoses in Taiwan. Acta Cardiol. 2005;60:51\u20133.","journal-title":"Acta Cardiol"},{"key":"1080_CR35","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10545-011-9359-8","volume":"34","author":"EA Braunlin","year":"2011","unstructured":"Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34:1183\u201397.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ymgme.2011.07.019","volume":"104","author":"DD Horovitz","year":"2011","unstructured":"Horovitz DD, Magalhaes Tde S, Pena e Costa A, Carelli LE, Souza e Silva D, de Linhares e Riello AP, et al. Spinal cord compression in young children with type VI mucopolysaccharidosis. Mol Genet Metab. 2011;104:295\u2013300.","journal-title":"Mol Genet Metab"},{"key":"1080_CR37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11325-013-0862-z","volume":"18","author":"CS Kasapkara","year":"2014","unstructured":"Kasapkara CS, Tumer L, Aslan AT, Hasanoglu A, Ezgu FS, Kucukcongar A, et al. Home sleep study characteristics in patients with mucopolysaccharidosis. Sleep Breath. 2014;18:143\u20139.","journal-title":"Sleep Breath"},{"key":"1080_CR38","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ppul.21309","volume":"45","author":"HY Lin","year":"2010","unstructured":"Lin HY, Chen MR, Lin CC, Chen CP, Lin DS, Chuang CK, et al. Polysomnographic characteristics in patients with mucopolysaccharidoses. Pediatr Pulmonol. 2010;45:1205\u201312.","journal-title":"Pediatr Pulmonol"},{"key":"1080_CR39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ymgme.2014.02.003","volume":"111","author":"HY Lin","year":"2014","unstructured":"Lin HY, Shih SC, Chuang CK, Lee KS, Chen MR, Lin HC, et al. Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses. Mol Genet Metab. 2014;111:533\u20138.","journal-title":"Mol Genet Metab"},{"key":"1080_CR40","doi-asserted-by":"crossref","unstructured":"Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB. Drugs R D. 2005;6:312\u20135.","DOI":"10.2165\/00126839-200506050-00008"},{"key":"1080_CR41","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/ajmg.a.36584","volume":"164A","author":"R Giugliani","year":"2014","unstructured":"Giugliani R, Lampe C, Guffon N, Ketteridge D, Leao-Teles E, Wraith JE, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI survey study. Am J Med Genet A. 2014;164A:1953\u201364.","journal-title":"Am J Med Genet A"},{"key":"1080_CR42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10545-011-9410-9","volume":"36","author":"CJ Hendriksz","year":"2013","unstructured":"Hendriksz CJ, Giugliani R, Harmatz P, Lampe C, Martins AM, Pastores GM, et al. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) clinical surveillance program (CSP). J Inherit Metab Dis. 2013;36:373\u201384.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR43","first-page":"89","volume":"3","author":"C Decker","year":"2010","unstructured":"Decker C, Yu ZF, Giugliani R, Schwartz IV, Guffon N, Teles EL, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med. 2010;3:89\u2013100.","journal-title":"J Pediatr Rehabil Med"},{"key":"1080_CR44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2017.03.008","volume":"122","author":"P Harmatz","year":"2017","unstructured":"Harmatz P, Hendriksz CJ, Lampe C, McGill JJ, Parini R, Leao-Teles E, et al. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Mol Genet Metab. 2017;122:107\u201312.","journal-title":"Mol Genet Metab"},{"key":"1080_CR45","first-page":"CD009806","volume":"3","author":"MJ Brunelli","year":"2016","unstructured":"Brunelli MJ, Atallah AN, da Silva EM. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. Cochrane Database Syst Rev. 2016;3:CD009806.","journal-title":"Cochrane Database Syst Rev"},{"key":"1080_CR46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","volume":"94","author":"P Harmatz","year":"2008","unstructured":"Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94:469\u201375.","journal-title":"Mol Genet Metab"},{"key":"1080_CR47","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"P Harmatz","year":"2006","unstructured":"Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533\u20139.","journal-title":"J Pediatr"},{"key":"1080_CR48","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","volume":"77","author":"JJ McGill","year":"2010","unstructured":"McGill JJ, Inwood AC, Coman DJ, Lipke ML, de Lore D, Swiedler SJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study. Clin Genet. 2010;77:492\u20138.","journal-title":"Clin Genet"},{"key":"1080_CR49","first-page":"317","volume":"17","author":"WM But","year":"2011","unstructured":"But WM, Wong MY, Chow JC, Chan WK, Ko WT, Wu SP, et al. Enzyme replacement therapy for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): experience in Hong Kong. Hong Kong Med J. 2011;17:317\u201324.","journal-title":"Hong Kong Med J"},{"key":"1080_CR50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10545-012-9481-2","volume":"36","author":"E Braunlin","year":"2013","unstructured":"Braunlin E, Rosenfeld H, Kampmann C, Johnson J, Beck M, Giugliani R, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(R)) therapy. J Inherit Metab Dis. 2013;36:385\u201394.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ymgme.2013.02.014","volume":"109","author":"DD Horovitz","year":"2013","unstructured":"Horovitz DD, Magalhaes TS, Acosta A, Ribeiro EM, Giuliani LR, Palhares DB, et al. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI. Mol Genet Metab. 2013;109:62\u20139.","journal-title":"Mol Genet Metab"},{"key":"1080_CR52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-8-51","volume":"8","author":"MM Brands","year":"2013","unstructured":"Brands MM, Hoogeveen-Westerveld M, Kroos MA, Nobel W, Ruijter GJ, Ozkan L, et al. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase. Orphanet J Rare Dis. 2013;8:51.","journal-title":"Orphanet J Rare Dis."},{"key":"1080_CR53","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2013.02.013","volume":"109","author":"MM Brands","year":"2013","unstructured":"Brands MM, Oussoren E, Ruijter GJ, Vollebregt AA, van den Hout HM, Joosten KF, et al. Up to five years experience with 11 mucopolysaccharidosis type VI patients. Mol Genet Metab. 2013;109:70\u20136.","journal-title":"Mol Genet Metab"},{"key":"1080_CR54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10545-013-9654-7","volume":"37","author":"PR Harmatz","year":"2014","unstructured":"Harmatz PR, Garcia P, Guffon N, Randolph LM, Shediac R, Braunlin E, et al. Galsulfase (Naglazyme(R)) therapy in infants with mucopolysaccharidosis VI. J Inherit Metab Dis. 2014;37:277\u201387.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR55","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000345635","volume":"48","author":"A Jurecka","year":"2012","unstructured":"Jurecka A, Opoka-Winiarska V, Jurkiewicz E, Marucha J, Tylki-Szymanska A. Spinal cord compression in Maroteaux-Lamy syndrome: case report and review of the literature with effects of enzyme replacement therapy. Pediatr Neurosurg. 2012;48:191\u20138.","journal-title":"Pediatr Neurosurg"},{"key":"1080_CR56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgmr.2015.09.002","volume":"5","author":"DDG Horovitz","year":"2015","unstructured":"Horovitz DDG, Acosta AX, de Rosso Giuliani L, Ribeiro EM. Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: six years follow-up of four children. Mol Genet Metab Rep. 2015;5:19\u201325.","journal-title":"Mol Genet Metab Rep"},{"key":"1080_CR57","unstructured":"Naglazyme Summary of Product Characteristics (EU). 2005. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000640\/WC500024289.pdf . Accessed 16 July 2018."},{"key":"1080_CR58","unstructured":"Naglazyme prescribing information (US). 2005. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/125117_0000_lbl.pdf . Accessed 16 Aug 2018."},{"key":"1080_CR59","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymgmr.2017.08.007","volume":"13","author":"M Furujo","year":"2017","unstructured":"Furujo M, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-year follow up. Mol Genet Metab Rep. 2017;13:69\u201375.","journal-title":"Mol Genet Metab Rep."},{"key":"1080_CR60","doi-asserted-by":"crossref","unstructured":"Franco JF, Soares DC, Torres LC, Leal GN, Cunha MT, Honjo RS, et al. Short communication impact of early enzyme-replacement therapy for mucopolysaccharidosis VI: results of a long-term follow-up of Brazilian siblings. Genet Mol Res. 2016;15(1).","DOI":"10.4238\/gmr.15017850"},{"key":"1080_CR61","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S1047951113000152","volume":"24","author":"GN Leal","year":"2014","unstructured":"Leal GN, de Paula AC, Morhy SS, Andrade JL, Kim CA. Advantages of early replacement therapy for mucopolysaccharidosis type VI: echocardiographic follow-up of siblings. Cardiol Young. 2014;24:229\u201335.","journal-title":"Cardiol Young"},{"key":"1080_CR62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ymgmr.2018.02.007","volume":"15","author":"CJ Hendriksz","year":"2018","unstructured":"Hendriksz CJ, Harmatz P, Giugliani R, Roberts J, Arul GS. Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders. Mol Genet Metab Rep. 2018;15:71\u20133.","journal-title":"Mol Genet Metab Rep."},{"key":"1080_CR63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymgmr.2017.10.003","volume":"13","author":"M McLoughlin","year":"2017","unstructured":"McLoughlin M, Stepien KM, McNelly B, Thompson L, Gorton J, Hendriksz CJ. The use of port-a-caths in adult patients with lysosomal storage disorders receiving enzyme replacement therapy-one Centre experience. Mol Genet Metab Rep. 2017;13:111\u20134.","journal-title":"Mol Genet Metab Rep."},{"key":"1080_CR64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","volume":"33","author":"P Harmatz","year":"2010","unstructured":"Harmatz P, Yu ZF, Giugliani R, Schwartz IV, Guffon N, Teles EL, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis. 2010;33:51\u201360.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR65","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.bmt.1705718","volume":"40","author":"JJ Boelens","year":"2007","unstructured":"Boelens JJ, Wynn RF, O'Meara A, Veys P, Bertrand Y, Souillet G, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007;40:225\u201333.","journal-title":"Bone Marrow Transplant"},{"key":"1080_CR66","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2012-09-455238","volume":"121","author":"JJ Boelens","year":"2013","unstructured":"Boelens JJ, Aldenhoven M, Purtill D, Ruggeri A, Defor T, Wynn R, et al. Outcomes of transplantation using various hematopoietic cell sources in children with hurler syndrome after myeloablative conditioning. Blood. 2013;121:3981\u20137.","journal-title":"Blood."},{"key":"1080_CR67","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ymgme.2016.01.011","volume":"117","author":"A Ghosh","year":"2016","unstructured":"Ghosh A, Miller W, Orchard PJ, Jones SA, Mercer J, Church HJ, et al. Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis type I: 10 year combined experience of 2 centres. Mol Genet Metab. 2016;117:373\u20137.","journal-title":"Mol Genet Metab"},{"key":"1080_CR68","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ymgmr.2014.04.001","volume":"1","author":"P Patel","year":"2014","unstructured":"Patel P, Suzuki Y, Tanaka A, Yabe H, Kato S, Shimada T, et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with hunter syndrome. Mol Genet Metab Rep. 2014;1:184\u201396.","journal-title":"Mol Genet Metab Rep."},{"key":"1080_CR69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/8904_2011_9","volume":"1","author":"DJ Coman","year":"2011","unstructured":"Coman DJ, Hayes IM, Collins V, Sahhar M, Wraith JE, Delatycki MB. Enzyme replacement therapy and extended newborn screening for mucopolysaccharidoses: opinions of treating physicians. JIMD Rep. 2011;1:9\u201315.","journal-title":"JIMD Rep"},{"key":"1080_CR70","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ymgmr.2015.03.011","volume":"3","author":"R Parini","year":"2015","unstructured":"Parini R, Rigoldi M, Tedesco L, Boffi L, Brambilla A, Bertoletti S, et al. Enzymatic replacement therapy for hunter disease: up to 9 years experience with 17 patients. Mol Genet Metab Rep. 2015;3:65\u201374.","journal-title":"Mol Genet Metab Rep."},{"issue":"11","key":"1080_CR71","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/gim.2018.29","volume":"20","author":"Julie B Eisengart","year":"2018","unstructured":"Eisengart JB, Rudser KD, Xue Y, Orchard P, Miller W, Lund T, et al. Long-term outcomes of systemic therapies for hurler syndrome: an international multicenter comparison. Genet Med. 2018;20(11):1423\u201329.","journal-title":"Genetics in Medicine"},{"key":"1080_CR72","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1023\/A:1005447232027","volume":"22","author":"E Herskhovitz","year":"1999","unstructured":"Herskhovitz E, Young E, Rainer J, Hall CM, Lidchi V, Chong K, et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis. 1999;22:50\u201362.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR73","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0194-5998(98)70371-7","volume":"118","author":"BC Papsin","year":"1998","unstructured":"Papsin BC, Vellodi A, Bailey CM, Ratcliffe PC, Leighton SE. Otologic and laryngologic manifestations of mucopolysaccharidoses after bone marrow transplantation. Otolaryngol Head Neck Surg. 1998;118:30\u20136.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"1080_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2012.05.115","volume":"167","author":"A Golda","year":"2013","unstructured":"Golda A, Jurecka A, Opoka-Winiarska V, Tylki-Szymanska A. Mucopolysaccharidosis type VI: a cardiologist's guide to diagnosis and treatment. Int J Cardiol. 2013;167:1\u201310.","journal-title":"Int J Cardiol"},{"key":"1080_CR75","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1750-1172-8-134","volume":"8","author":"S Jester","year":"2013","unstructured":"Jester S, Larsson J, Eklund EA, Papadopoulou D, Mansson JE, Bekassy AN, et al. Haploidentical stem cell transplantation in two children with mucopolysaccharidosis VI: clinical and biochemical outcome. Orphanet J Rare Dis. 2013;8:134.","journal-title":"Orphanet J Rare Dis."},{"key":"1080_CR76","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymgme.2010.09.010","volume":"102","author":"S Turbeville","year":"2011","unstructured":"Turbeville S, Nicely H, Rizzo JD, Pedersen TL, Orchard PJ, Horwitz ME, et al. Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. Mol Genet Metab. 2011;102:111\u20135.","journal-title":"Mol Genet Metab"},{"key":"1080_CR77","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0161-6420(89)32795-3","volume":"96","author":"CG Summers","year":"1989","unstructured":"Summers CG, Purple RL, Krivit W, Pineda R 2nd, Copland GT, Ramsay NK, et al. Ocular changes in the mucopolysaccharidoses after bone marrow transplantation. A preliminary report. Ophthalmology. 1989;96:977\u201384 discussion 84-5.","journal-title":"Ophthalmology."},{"key":"1080_CR78","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0161-6420(98)96014-6","volume":"105","author":"EO Gullingsrud","year":"1998","unstructured":"Gullingsrud EO, Krivit W, Summers CG. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up. Ophthalmology. 1998;105:1099\u2013105.","journal-title":"Ophthalmology."},{"key":"1080_CR79","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.bbmt.2014.11.112","volume":"21","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Jones S, Bonney D, Borrill R, Coussons M, Mercer J, et al. Hematopoietic cell transplantation for MPS patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant. 2015;21:S93.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1080_CR80","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/bjh.13059","volume":"167","author":"JJ Boelens","year":"2014","unstructured":"Boelens JJ, Orchard PJ, Wynn RF. Transplantation in inborn errors of metabolism: current considerations and future perspectives. Br J Haematol. 2014;167:293\u2013303.","journal-title":"Br J Haematol"},{"key":"1080_CR81","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1542\/peds.2012-1671","volume":"130","author":"CL Marcus","year":"2012","unstructured":"Marcus CL, Brooks LJ, Draper KA, Gozal D, Halbower AC, Jones J, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012;130:576\u201384.","journal-title":"Pediatrics."},{"key":"1080_CR82","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ijporl.2014.03.021","volume":"78","author":"B Gonuldas","year":"2014","unstructured":"Gonuldas B, Yilmaz T, Sivri HS, Gucer KS, Kilinc K, Genc GA, et al. Mucopolysaccharidosis: Otolaryngologic findings, obstructive sleep apnea and accumulation of glucosaminoglycans in lymphatic tissue of the upper airway. Int J Pediatr Otorhinolaryngol. 2014;78:944\u20139.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"1080_CR83","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.prrv.2010.10.005","volume":"12","author":"MS Muhlebach","year":"2011","unstructured":"Muhlebach MS, Wooten W, Muenzer J. Respiratory manifestations in mucopolysaccharidoses. Paediatr Respir Rev. 2011;12:133\u20138.","journal-title":"Paediatr Respir Rev"},{"key":"1080_CR84","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10545-012-9555-1","volume":"36","author":"KI Berger","year":"2013","unstructured":"Berger KI, Fagondes SC, Giugliani R, Hardy KA, Lee KS, McArdle C, et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis. 2013;36:201\u201310.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR85","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2017.08.008","volume":"122S","author":"DM Rapoport","year":"2017","unstructured":"Rapoport DM, Mitchell JJ. Pathophysiology, evaluation, and management of sleep disorders in the mucopolysaccharidoses. Mol Genet Metab. 2017;122S:49\u201354.","journal-title":"Mol Genet Metab"},{"key":"1080_CR86","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cphy.c140008","volume":"4","author":"AJ Piper","year":"2014","unstructured":"Piper AJ, Yee BJ. Hypoventilation syndromes. Compr Physiol. 2014;4:1639\u201376.","journal-title":"Compr Physiol"},{"key":"1080_CR87","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1378\/chest.97.6.1496","volume":"97","author":"AS Ginzburg","year":"1990","unstructured":"Ginzburg AS, Onal E, Aronson RM, Schild JA, Mafee MF, Lopata M. Successful use of nasal-CPAP for obstructive sleep apnea in hunter syndrome with diffuse airway involvement. Chest. 1990;97:1496\u20138.","journal-title":"Chest."},{"key":"1080_CR88","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1034\/j.1399-3003.1999.13e42.x","volume":"13","author":"O Orliaguet","year":"1999","unstructured":"Orliaguet O, Pepin JL, Veale D, Kelkel E, Pinel N, Levy P. Hunter's syndrome and associated sleep apnoea cured by CPAP and surgery. Eur Respir J. 1999;13:1195\u20137.","journal-title":"Eur Respir J"},{"key":"1080_CR89","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1440-1754.2003.00218.x","volume":"39","author":"D Chan","year":"2003","unstructured":"Chan D, Li AM, Yam MC, Li CK, Fok TF. Hurler's syndrome with cor pulmonale secondary to obstructive sleep apnoea treated by continuous positive airway pressure. J Paediatr Child Health. 2003;39:558\u20139.","journal-title":"J Paediatr Child Health"},{"key":"1080_CR90","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10545-012-9563-1","volume":"36","author":"R Walker","year":"2013","unstructured":"Walker R, Belani KG, Braunlin EA, Bruce IA, Hack H, Harmatz PR, et al. Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis. 2013;36:211\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR91","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0310057X9602400408","volume":"24","author":"C Moores","year":"1996","unstructured":"Moores C, Rogers JG, McKenzie IM, Brown TC. Anaesthesia for children with mucopolysaccharidoses. Anaesth Intensive Care. 1996;24:459\u201363.","journal-title":"Anaesth Intensive Care"},{"key":"1080_CR92","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1365-2044.1994.tb04360.x","volume":"49","author":"RW Walker","year":"1994","unstructured":"Walker RW, Darowski M, Morris P, Wraith JE. Anaesthesia and mucopolysaccharidoses. A review of airway problems in children. Anaesthesia. 1994;49:1078\u201384.","journal-title":"Anaesthesia."},{"key":"1080_CR93","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1460-9592.2012.03825.x","volume":"22","author":"G Frawley","year":"2012","unstructured":"Frawley G, Fuenzalida D, Donath S, Yaplito-Lee J, Peters H. A retrospective audit of anesthetic techniques and complications in children with mucopolysaccharidoses. Paediatr Anaesth. 2012;22:737\u201344.","journal-title":"Paediatr Anaesth"},{"key":"1080_CR94","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1460-9592.2012.03904.x","volume":"22","author":"MC Theroux","year":"2012","unstructured":"Theroux MC, Nerker T, Ditro C, Mackenzie WG. Anesthetic care and perioperative complications of children with Morquio syndrome. Paediatr Anaesth. 2012;22:901\u20137.","journal-title":"Paediatr Anaesth"},{"key":"1080_CR95","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1460-9592.2003.00969.x","volume":"13","author":"RW Walker","year":"2003","unstructured":"Walker RW, Colovic V, Robinson DN, Dearlove OR. Postobstructive pulmonary oedema during anaesthesia in children with mucopolysaccharidoses. Paediatr Anaesth. 2003;13:441\u20137.","journal-title":"Paediatr Anaesth"},{"key":"1080_CR96","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1460-9592.1997.d01-102.x","volume":"7","author":"RW Walker","year":"1997","unstructured":"Walker RW, Allen DL, Rothera MR. A fibreoptic intubation technique for children with mucopolysaccharidoses using the laryngeal mask airway. Paediatr Anaesth. 1997;7:421\u20136.","journal-title":"Paediatr Anaesth"},{"key":"1080_CR97","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF03010548","volume":"35","author":"IA Herrick","year":"1988","unstructured":"Herrick IA, Rhine EJ. The mucopolysaccharidoses and anaesthesia: a report of clinical experience. Can J Anaesth. 1988;35:67\u201373.","journal-title":"Can J Anaesth"},{"key":"1080_CR98","first-page":"S141","volume":"120","author":"M Wood","year":"2017","unstructured":"Wood M, JE D AM, DM E. Guided growth surgery for genu valgum in mucopolysaccharidosis type VI. Mol Genet Metab. 2017;120:S141.","journal-title":"Mol Genet Metab"},{"key":"1080_CR99","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s11999-015-4437-0","volume":"473","author":"B Pruszczynski","year":"2015","unstructured":"Pruszczynski B, Mackenzie WG, Rogers K, White KK. Spinal cord injury after extremity surgery in children with thoracic kyphosis. Clin Orthop Relat Res. 2015;473:3315\u201320.","journal-title":"Clin Orthop Relat Res"},{"key":"1080_CR100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11832-014-0601-4","volume":"8","author":"KK White","year":"2014","unstructured":"White KK, Jester A, Bache CE, Harmatz PR, Shediac R, Thacker MM, et al. Orthopedic management of the extremities in patients with Morquio a syndrome. J Child Orthop. 2014;8:295\u2013304.","journal-title":"J Child Orthop"},{"key":"1080_CR101","doi-asserted-by":"crossref","first-page":"E539","DOI":"10.1097\/00007632-200112010-00020","volume":"26","author":"SS Dalvie","year":"2001","unstructured":"Dalvie SS, Noordeen MH, Vellodi A. Anterior instrumented fusion for thoracolumbar kyphosis in mucopolysaccharidosis. Spine (Phila Pa 1976). 2001;26:E539\u201341.","journal-title":"Spine (Phila Pa 1976)"},{"key":"1080_CR102","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ymgme.2016.06.001","volume":"118","author":"GA Solanki","year":"2016","unstructured":"Solanki GA, Sun PP, Martin KW, Hendriksz CJ, Lampe C, Guffon N, et al. Cervical cord compression in mucopolysaccharidosis VI (MPS VI): findings from the MPS VI clinical surveillance program (CSP). Mol Genet Metab. 2016;118:310\u20138.","journal-title":"Mol Genet Metab"},{"key":"1080_CR103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2005.11.007","volume":"51","author":"JL Ashworth","year":"2006","unstructured":"Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol. 2006;51:1\u201317.","journal-title":"Surv Ophthalmol"},{"key":"1080_CR104","first-page":"32","volume":"7","author":"LSWG Leung","year":"1971","unstructured":"Leung LSWG, Hobson RR. Further electroretinographic studies of patients with mucopolysaccharidoses. Birth Defects Orig Artic Ser. 1971;7:32\u201340.","journal-title":"Birth Defects Orig Artic Ser"},{"key":"1080_CR105","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/archophthalmol.2010.341","volume":"129","author":"ED Bothun","year":"2011","unstructured":"Bothun ED, Decanini A, Summers CG, Orchard PJ, Tolar J. Outcome of penetrating keratoplasty for mucopolysaccharidoses. Arch Ophthalmol. 2011;129:138\u201344.","journal-title":"Arch Ophthalmol"},{"key":"1080_CR106","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/bjophthalmol-2016-308807","volume":"101","author":"KL Ohden","year":"2017","unstructured":"Ohden KL, Pitz S, Ashworth J, Magalhaes A, Marinho DR, Lindahl P, et al. Outcomes of keratoplasty in the mucopolysaccharidoses: an international perspective. Br J Ophthalmol. 2017;101:909\u201312.","journal-title":"Br J Ophthalmol"},{"key":"1080_CR107","doi-asserted-by":"crossref","unstructured":"Keane M, Coster D, Ziaei M, Williams K. Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus. Cochrane Database Syst Rev. 2014;(7):CD009700.","DOI":"10.1002\/14651858.CD009700.pub2"},{"key":"1080_CR108","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2147\/OPTH.S78368","volume":"9","author":"CR Fenzl","year":"2015","unstructured":"Fenzl CR, Teramoto K, Moshirfar M. Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses. Clin Ophthalmol. 2015;9:1633\u201344.","journal-title":"Clin Ophthalmol"},{"key":"1080_CR109","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0363-5023(98)80120-2","volume":"23","author":"AE Van Heest","year":"1998","unstructured":"Van Heest AE, House J, Krivit W, Walker K. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J Hand Surg Am. 1998;23:236\u201343.","journal-title":"J Hand Surg Am"},{"key":"1080_CR110","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/0883073807300528","volume":"22","author":"A Yuen","year":"2007","unstructured":"Yuen A, Dowling G, Johnstone B, Kornberg A, Coombs C. Carpal tunnel syndrome in children with mucopolysaccaridoses. J Child Neurol. 2007;22:260\u20133.","journal-title":"J Child Neurol"},{"key":"1080_CR111","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/BF01991908","volume":"154","author":"CF Wippermann","year":"1995","unstructured":"Wippermann CF, Beck M, Schranz D, Huth R, Michel-Behnke I, Jungst BK. Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr. 1995;154:98\u2013101.","journal-title":"Eur J Pediatr"},{"key":"1080_CR112","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/01.CIR.85.1.188","volume":"85","author":"CT Tan","year":"1992","unstructured":"Tan CT, Schaff HV, Miller FA Jr, Edwards WD, Karnes PS. Valvular heart disease in four patients with Maroteaux-Lamy syndrome. Circulation. 1992;85:188\u201395.","journal-title":"Circulation."},{"key":"1080_CR113","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02559995","volume":"11","author":"M Hachida","year":"1996","unstructured":"Hachida M, Nonoyama M, Bonkohara Y, Hanayama N, Koyanagi H. Combined aortic and mitral valve replacement in an adult with mucopolysaccharidosis (Maroteaux-Lamy syndrome). Heart Vessel. 1996;11:215\u20137.","journal-title":"Heart Vessel"},{"key":"1080_CR114","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/pgmj.68.798.287","volume":"68","author":"TH Marwick","year":"1992","unstructured":"Marwick TH, Bastian B, Hughes CF, Bailey BP. Mitral stenosis in the Maroteaux-Lamy syndrome: a treatable cause of dyspnoea. Postgrad Med J. 1992;68:287\u20138.","journal-title":"Postgrad Med J"},{"key":"1080_CR115","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10545-012-9474-1","volume":"35","author":"A Thumler","year":"2012","unstructured":"Thumler A, Miebach E, Lampe C, Pitz S, Kamin W, Kampmann C, et al. Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series. J Inherit Metab Dis. 2012;35:1071\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"1080_CR116","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.athoracsur.2015.11.062","volume":"102","author":"S Torre","year":"2016","unstructured":"Torre S, Scarpelli M, Salviati A, Buffone E, Faggian G, Luciani GB. Aortic and mitral valve involvement in Maroteaux-Lamy syndrome VI: surgical implications in the enzyme replacement therapy era. Ann Thorac Surg. 2016;102:e23\u20135.","journal-title":"Ann Thorac Surg"},{"key":"1080_CR117","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.carpath.2006.11.009","volume":"16","author":"GY Oudit","year":"2007","unstructured":"Oudit GY, Butany J, Williams WG, Siu SC, Clarke JT, Iwanochko RM. Left ventricular aneurysm in a patient with mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): clinical and pathological correlation. Cardiovasc Pathol. 2007;16:237\u201340.","journal-title":"Cardiovasc Pathol"},{"key":"1080_CR118","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739\u201391.","journal-title":"Eur Heart J"},{"key":"1080_CR119","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","volume":"70","author":"RA Nishimura","year":"2017","unstructured":"Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252\u201389.","journal-title":"J Am Coll Cardiol"},{"key":"1080_CR120","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijporl.2005.01.017","volume":"69","author":"MA Simmons","year":"2005","unstructured":"Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP. Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2005;69:589\u201395.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"1080_CR121","first-page":"267","volume":"33","author":"M Mesolella","year":"2013","unstructured":"Mesolella M, Cimmino M, Cantone E, Marino A, Cozzolino M, Della Casa R, et al. Management of otolaryngological manifestations in mucopolysaccharidoses: our experience. Acta Otorhinolaryngol Ital. 2013;33:267\u201372.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"1080_CR122","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.ijporl.2014.06.027","volume":"78","author":"SS Sudarsan","year":"2014","unstructured":"Sudarsan SS, Paramasivan VK, Arumugam SV, Murali S, Kameswaran M. Comparison of treatment modalities in syndromic children with obstructive sleep apnea--a randomized cohort study. Int J Pediatr Otorhinolaryngol. 2014;78:1526\u201333.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"1080_CR123","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/ALN.0b013e31827773b2","volume":"118","author":"JL Apfelbaum","year":"2013","unstructured":"Apfelbaum JL, Hagberg CA, Caplan RA, Blitt CD, Connis RT, Nickinovich DG, et al. Practice guidelines for management of the difficult airway: an updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Anesthesiology. 2013;118:251\u201370.","journal-title":"Anesthesiology."},{"key":"1080_CR124","unstructured":"Society DA. DAS Paediatric Difficult Airway Guidelines. 2015. https:\/\/www.das.uk.com\/guidelines\/downloads.html . Accessed 28 June 2018."},{"key":"1080_CR125","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1177\/0194599811409837","volume":"145","author":"PS Roland","year":"2011","unstructured":"Roland PS, Rosenfeld RM, Brooks LJ, Friedman NR, Jones J, Kim TW, et al. Clinical practice guideline: polysomnography for sleep-disordered breathing prior to tonsillectomy in children. Otolaryngol Head Neck Surg. 2011;145:S1\u201315.","journal-title":"Otolaryngol Head Neck Surg."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1080-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1080-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1080-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T16:44:31Z","timestamp":1721321071000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1080-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1080"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1080-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"assertion":[{"value":"2 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P Harmatz has conducted consultancy work and\/or has received grant support from Alexion, Armagen, BioMarin Pharmaceutical Inc., Chiesi, Denali, Genzyme, Enzyvant, Inventiva, JCR Pharmaceuticals, Orphazyme, Pfizer, PTC Therapeutics, RegenXbio, Sangamo, Shire, SOBI and Ultragenyx. C Hendriksz; is Owner and Director of FYMCA Medical Ltd.; has conducted consultancy work for Actelion, Amicus, Alexion, Audentes, BioMarin Pharmaceutical Inc., Chiesi, Evidera, Inventiva, GSK, SOBI, Health Care at Home, Sanofi Genzyme, Shire. R Giugliani has received consultancy fees, and\/or investigator fees, and\/or speaker honoraria and\/or travel grants to attend scientific meetings from Actelion, Amicus, Armagen, BioMarin, Chiesi, GC Pharma, Inventiva, JCR Pharmaceuticals, Lysogene, RegenxBio, Sanofi Genzyme, Shire, Sobi, and Ultragenyx. M Scarpa has received honoraria, research and travel grants from Alexion, BioMarin Pharmaceutical Inc., Chiesi, Sanofi Genzyme, Shire, Ultragenix and Sangamo. MU Akyol has received speaker honoraria and travel grants from Shire. J Ashworth has received honoraria, travel expenses and a research grant from BioMarin Pharmaceutical Inc. and has received consultancy fees from AbbVie and Inventiva. T Alden has received consultant and honoraria payments from BioMarin Pharmaceutical Inc. and Shire. K Belani was a co-investigator on several studies funded by grants from Lysogene and Shire and has received a travel grant from BioMarin Pharmaceutical Inc. for attendance at an advisory meeting. H Amartino has conducted investigator, speaker and consultant work for Amicus, BioMarin Pharmaceutical Inc., Bluebird Bio, Sanofi Genzyme and Shire. K Berger has received consultancy and honoraria payments from BioMarin Pharmaceutical Inc. and Sanofi Genzyme. A Borgo has received travel grants and honoraria from BioMarin Pharmaceutical Inc., and honoraria from Brains for Brains and Shire. E Braunlin has received speaker and travel grants from BioMarin Pharmaceutical Inc. and Sanofi Genzyme, a research funding from BioMarin Pharmaceutical Inc. and Bluebird Bio and has conducted consultancy work for Ultragenyx. Y Eto has received research grants and honoraria from BioMarin Pharmaceutical Inc., Alexion Pharmaceutical Inc., Sanofi Genzym and Actelion Pharmaceuticals Ltd., and honoraria from Dainippon Sumitomo Inc., Japan Chemical Research and Shire Japan. JI Gold has received honoraria and travel grants from BioMarin Pharmaceutical Inc. A Jester has received honoraria, travel grants, and research funding from BioMarin Pharmaceutical Inc. and funding from Shire for equipment to conduct outcomes assessment. S Jones has conducted investigator, speaker and consultancy work for Alexion, BioMarin Pharmaceutical Inc., Orchard therapeutics, Sanofi Genzyme, Shire and Ultragenyx. C Karsli has nothing to disclose. W MacKenzie has received travel grants and honoraria from BioMarin Pharmaceutical Inc. and has conducted consultancy work for Johnson & Johnson. A McFadyen has received unrestricted educational grants from Alexion, BioMarin Pharmaceutical Inc., Sanofi Genzyme, Shire, and Johnson and Johnson. J McGill has conducted speaker, consultancy, board member work and received travel grants from Actelion, BioMarin Pharmaceutical Inc., Sanofi Genzyme and Shire. He has been an investigator for BioMarin Pharmaceutical Inc. J Mitchell has received research support, advisory board fees, and travel grants from BioMarin Pharmaceutical Inc. and has been involved in the conduct of BioMarin clinical trials. He has also received research funding from Sanofi Genzyme and Shire. He has received consultancy fees from Ultragenyx, BioMarin Pharmaceutical Inc., Sanofi Genzyme and Shire. J Muenzer has conducted consultancy work and\/or has received grant support from BioMarin Pharmaceutical Inc., Denali, Green Cross, Eloxx, PTC Therapeutics, RegenXbio, Sangamo, Sanofi Genzyme, Shire and Sobi. T Okuyama has received research grant from BioMarin Pharmaceutical Inc., Green Cross, Sanofi Genzyme, Shire, Orchard Therapeutics, and JCR, and has attended advisory boards for Sanofi Genzyme. He is Principal Investigator for ERT clinical trials for MPS II sponsored by Green Cross and JCR. P Orchard has received honoraria, travel and research support from Sanofi Genzyme, and has received research support from BioMarin Pharmaceutical Inc., Bluebird Bio and Horizon Pharma. B Stevens has received grants for the MPS Society from Sanofi Genzyme, Shire, Sangamo, Regenxbio, BioMarin Pharmaceuticals Inc. and Ultragenyx for direct advocacy, expert meetings, literature and travel. S Thomas has received grants for the MPS Society from Sanofi Genzyme, Shire, Sangamo, Regenxbio, BioMarin Pharmaceuticals Inc., Chiesi and Ultragenyx for direct advocacy, expert meetings, honoraria, literature and travel. DR Marinho has received honoraria and travel grants from BioMarin Pharmaceutical Inc. R Walker has received travel grants, honorarium and payments for consulting work from BioMarin Pharmaceutical Inc., Sanofi Genzyme and Shire. R Wynn has conducted consultancy work for Chimerix, Bluebird Bio and Orchard Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"118"}}